% | $
Quotes you view appear here for quick access.

FRX Message Board

  • ricky_rooster ricky_rooster Mar 25, 2010 10:19 PM Flag

    I'm surprised no hype on the april 7th fda advisory panel?

    with ITMN going from 13 to 47 on the fda advisory panel, I am surprised that FRX is not getting more press about their upcoming april 7th advisory panel meeting with May 20th PDUFA fda date.

    Any ideas?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ITMN has potential billion dollar market ... not sure what the market is FRX's drug.

    • actually looking at the options for the april 32.50's there is more action than historic. plus there is an analyst day at lazard tommorrow to discuss...
      (disclaimer - i have positions in the april 32.50 calls)

      Mar 29, 2010 ( via COMTEX) -- 09:33 EDT Lazard Healthcare/Pharma Analyst Research Team holds a conference call - The Healthcare/Pharmaceuticals Analyst Research Team discusses Forest Laboratories, Inc's (FRX) Daxas, a proprietary selective Phosphodiesterase 4 (PDE4) enzyme inhibitor developed by Nycomed and Forest Laboratories Holdings Ltd, a wholly-owned subsidiary of FRX, for treatment of COPD (Chronic Obstructive Pulmonary Disease) on an Analyst/Industry conference call to be held on March 30 at 2 pm hosted by Lazard Capital.